Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT06238024

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06238024
Other papers using this trial's data
  • Effect of IL-6 receptor inhibition on infarct volume after endovascular treatment for ischaemic stroke: a phase 2, randomised, placebo-controlled trial EBioMedicine, 2026-03 DOI, PubMed 41687453, PMC12917384 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06238024. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-02 (actual); primary completion 2024-06-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment
Acronym
IRIS
Condition
Interleukin-6
Condition
Endovascular Treatment
Intervention (Drug)
Tocilizumab
Intervention (Drug)
NaCl 0.9% 100ml
Lead sponsor
Suzhou Municipal Hospital of Anhui Province (class: other)
Collaborator
Xuanwu Hospital, Beijing (class: other)

Record details

Record id
cardio:ct-nct06238024
Content hash
fb10f0868e6124cd6d0e33fb4d46b06ccbee0308b18d14db984ed5bedcadf96c